<DOC>
	<DOCNO>NCT00656734</DOCNO>
	<brief_summary>To determine high safest tolerate dose MDX-1411 treatment clear cell renal cell carcinoma ( Kidney cancer ) .</brief_summary>
	<brief_title>Study MDX-1411 Given Every 14 Days With Pre-medications Subjects With Clear Cell Kidney Cancer .</brief_title>
	<detailed_description>Subjects assign one dose upon enrollment continue dose throughout study . The maximum duration study two half year total 17 cycle .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Histologically confirm diagnosis RCC clear cell component Measurable disease Treated 6 prior systemic therapy advanced/recurrent disease become intolerant systemic therapy Subjects treat brain metastasis must without magnetic resonance imaging ( MRI ) evidence progression least 8 week steroids least 4 week eligible At least 28 day since last chemotherapy At least 28 day first dose MDX 1411 since major surgery ECOG performance status 02 No known positivity human immunodeficiency virus ( HIV ) , Hep B C Previous treatment antiCD70 antibody Active infection require i.v systemic therapy within 28 day first dose Evidence bleed diathesis coagulopathy Active autoimmune disease require immunosuppressive therapy Known current drug alcohol abuse Any underlie medical condition make administration MDX 1411 hazardous Psychiatric illness social situation would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Medarex Inc .</keyword>
</DOC>